Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0013395 (
dyspepsia
)
4,879
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This study assessed the gastric acid antisecretory effect of DLBS2411 fractionated from Cinnamomum burmannii. Hydrogen potassium adenosine triphosphatase (H(+)/K(+)
ATPase
) activity and its gene expression were observed, and the antioxidant activity of DLBS2411 was also investigated. Treatment of DLBS2411 decreased the level of H(+)/K(+)
ATPase
messenger RNA expression on human embryonic kidney 293 cells and rat gastric parietal cells in a dose-dependent manner, in vitro and ex vivo. DLBS2411 also acted as a competitive inhibitor by showing inhibition in gastric H(+)/K(+)
ATPase
activity at various pHs. In gastric ulcer animal models induced with indomethacin and ethanol, DLBS2411showed a reduction in the number of petechiae, suggesting that the fraction also confers gastroprotective activity. Moreover, DLBS2411 was also found to have potent antioxidant activity. Taken together, DLBS2411 is a promising novel agent for the management of
dyspepsia
, a condition of hyperacidity and diseases in the stomach requiring gastroprotection.
...
PMID:Hydrogen potassium adenosine triphosphatase activity inhibition and downregulation of its expression by bioactive fraction DLBS2411 from Cinnamomum burmannii in gastric parietal cells. 2410 79
The first histamine H
2
receptor antagonists (H
2
RAs) were developed in the early 1970s. They played a dominant role in treating peptic ulcer disease and gastroesophageal reflux disease (GERD). H
2
RAs block the production of acid by H
+
, K
+
-
ATPase
at the parietal cells and produce gastric luminal anacidity for varying periods. H
2
RAs are highly selective, and they do not affect H1 receptors. Moreover, they are not anticholinergic agents. Sequential development of H
2
RAs, proton pump inhibitors (PPIs), and discovery of
Helicobacter pylori
infection changed the paradigm of peptic ulcer disease with marked decrease of morbidity and mortality. PPIs are known to be the most effective drugs that are currently available for suppressing gastric acid secretion. Many studies have shown its superiority over H
2
RAs as a treatment for acid-related disorders, such as peptic ulcer disease, GERD, and Zollinger-Ellison syndrome. However, other studies have reported that PPIs may not be able to render stomach achlorhydric and have identified a phenomenon of increasing gastric acidity at night in individuals receiving a PPI twice daily. These nocturnal acid breakthrough episodes can be eliminated with an addition of H
2
RAs at night. The effectiveness of nighttime dose of H
2
RA suggests a major role of histamine in nocturnal acid secretion. H
2
RAs reduce secretion of gastric acid, and each H
2
RA also has specific effects. For instance, nizitidine alleviates not only symptoms of GERD, but also provokes gastric emptying, resulting in clinical symptom improvement of functional
dyspepsia
. The aim of this paper was to review the characteristics and role of H
2
RAs and assess the future strategy and treatment of upper gastrointestinal disease, including acid related disorders.
...
PMID:The Effect of H
2
Receptor Antagonist in Acid Inhibition and Its Clinical Efficacy. 2872 10
